{"title":"Cervical Cancer","description":null,"products":[{"product_id":"cadonilimab","title":"Cadonilimab","description":"\u003cp\u003eCadonilimab is a bispecific antibody that targets the PD-1 and CTLA-4 receptors on tumor cells to treat various solid cancers. In June 2022, cadonilimab was approved in China for use in patients with relapsed or metastatic cervical cancer.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eCadonilimab \u003c\/span\u003esold under the brand name 开坦尼® in china.\u003c\/li\u003e\u003c\/ul\u003e","brand":"Akeso, Inc, China","offers":[{"title":"Default Title","offer_id":44797956816939,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0837.jpg?v=1787022270"},{"product_id":"socazolimab","title":"Socazolimab","description":"\u003cp\u003eSocazolimab is a fully human anti-PD-L1 (programmed cell death 1 ligand 1) monoclonal antibody, an immune checkpoint inhibitor, developed by Sorrento.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eSocazolimab \u003c\/span\u003esold under the brand name 善克钰® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eOn December 21, 2023, the official website of the China National Medical Products Administration (NMPA) announced that the anti-PD-L1 monoclonal antibody socazolimab, applied for by Zhaoke Oncology, a subsidiary of Lee's Pharmaceutical, has been officially approved for the treatment of recurrent or metastatic cervical cancer.\u003c\/p\u003e","brand":"Lee's Pharmaceutical, China","offers":[{"title":"Default Title","offer_id":44797956849707,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0918.jpg?v=1787022271"},{"product_id":"enlonstobart","title":"Enlonstobart","description":"\u003cp\u003eEnlonstobart, a recombinant, fully humanised immunoglobulin G4 monoclonal antibody targeted against programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eEnlonstobart \u003c\/span\u003esold under the brand name 恩舒幸 (Enshuxing) ® in china. \u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eEnlonstobart received its first approval (a conditional marketing authorisation) in June 2024, in China, for use in patients with recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer who have failed previous platinum-containing chemotherapy. \u003c\/p\u003e","brand":"CSPC Pharmaceutical Group, China","offers":[{"title":"Default Title","offer_id":44797956915243,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-1067.jpg?v=1787022272"},{"product_id":"iparomlimab-tuvonralimab","title":"Iparomlimab\/tuvonralimab","description":"\u003cp class=\"dictionary-definiton__term-title\" data-cdr-id=\"798992\"\u003e\u003cstrong\u003eAbout Iparomlimab\/Tuvonralimab\u003c\/strong\u003e\u003c\/p\u003e\u003cdiv class=\"dictionary-definiton__term-definition\"\u003e\n\u003cdiv class=\"dictionary-definiton__definition\"\u003eA mixture of the two engineered monoclonal antibodies iparomlimab, which is an immunoglobulin G4 (IgG4) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and tuvonralimab, which is an IgG1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of iparomlimab\/tuvonralimab, iparomlimab and tuvonralimab target and bind to PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs), respectively. This inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eIparomlimab\/Tuvonralimab \u003c\/span\u003esold under the brand name 齐倍安® in china.\u003c\/li\u003e\u003c\/ul\u003e\n\u003cp\u003eOn September 30, 2024, China's National Medical Products Administration (NMPA) announced the conditional approval of (Iparomlimab\/tuvonralimab) injection for the treatment of patients with recurrent or metastatic cervical cancer who have failed previous platinum-containing chemotherapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Qilu Pharmacy Limited Company, China","offers":[{"title":"Default Title","offer_id":44797957111851,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-1525.jpg?v=1787022275"}],"url":"https:\/\/xomeds.com\/collections\/cervical-cancer.oembed","provider":"XOMEDS","version":"1.0","type":"link"}